Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow announced presentations of three studies supporting its ophthalmic products IHEEZO (chloroprocaine HCl ophthalmic gel) and BYOOVIZ (ranibizumab-nuna biosimilar) at the ASRS 2026 Annual Meeting. Interim findings from a randomized study showed IHEEZO demonstrated encouraging trends toward less post-injection pain and better patient experience compared to subconjunctival lidocaine. A large real-world analysis of nearly 20,000 injections found no increased endophthalmitis risk with IHEEZO. The company continues enrollment in the QUELL clinical trial with topline data expected in Q4 2026.